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Abstract The mTOR complex 1 (mTORC1) and endoplasmic reticulum (ER) stress pathways are
critical regulators of intestinal inflammation and colon cancer growth. Sestrins are stress-inducible
proteins, which suppress both mTORC1 and ER stress; however, the role of Sestrins in colon
physiology and tumorigenesis has been elusive due to the lack of studies in human tissues or in
appropriate animal models. In this study, we show that human SESN2 expression is elevated in the
colon of ulcerative colitis patients but is lost upon p53 inactivation during colon carcinogenesis. In
mouse colon, Sestrin2 was critical for limiting ER stress and promoting the recovery of epithelial
cells after inflammatory injury. During colitis-promoted tumorigenesis, Sestrin2 was shown to be an
important mediator of p53’s control over mTORC1 signaling and tumor cell growth. These results
highlight Sestrin2 as a novel tumor suppressor, whose downregulation can accelerate both colitis
and colon carcinogenesis.
DOI: 10.7554/eLife.12204.001
Introduction
Colorectal carcinoma (CRC) is an important contributor to cancer mortality and morbidity. The life-
time risk of developing CRC in the US is 4–5%, and approximately one-third of CRC patients die
from the disease (Siegel et al, 2015). Although the pathogenetic mechanisms underlying CRC devel-
opment are complex and heterogeneous, several critical genes and pathways important in its initia-
tion and progression are well characterized, such as Wnt-APC, Ras-MAPK, p53 and DNA repair
pathways (Fearon, 2011). In addition to these components, mammalian target of rapamycin com-
plex 1 (mTORC1), a protein kinase that is essential for cell growth (Hay and Sonenberg, 2004;
Zoncu et al, 2011), was recently found to play a key tumorigenic role during CRC development
induced by either colitis (Thiem et al, 2013) or a genetic mutation (Faller et al, 2015;
Hardiman et al, 2014).
In addition to promoting cancer cell growth, mTORC1 hyperactivation can lead to unrestricted
protein synthesis, resulting in the accumulation of unfolded protein, endoplasmic reticulum (ER)
stress and tissue injury (Ozcan et al, 2008; Park et al, 2014; Young et al, 2013), which together
can contribute to tumor progression (Wang and Kaufman, 2014). ER stress has been shown to be
critically involved in the pathogenesis of colitis and colon inflammation (Bertolotti et al, 2001;
Cao et al, 2013; Kaser et al, 2008), which is an important risk factor of CRC development
(Thorsteinsdottir et al, 2011) and a well-characterized tumor promoter (Grivennikov et al, 2012;
Terzic et al, 2010). Mechanisms of how the mTORC1 and ER stress signaling pathways are
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regulated in the colon, especially during colon injury, inflammation and tumorigenesis, are poorly
understood.
Sestrins are a family of stress-inducible proteins that are widely conserved throughout animal spe-
cies (Lee et al, 2013). Sestrins were originally identified as a target of the tumor suppressor p53
(Budanov et al, 2002; Velasco-Miguel et al, 1999). Sestrins have two important functions, suppress-
ing reactive oxygen species (ROS) (Budanov et al, 2004) and inhibiting mTORC1 (Budanov and
Karin, 2008). The ROS-suppressing effect of Sestrins is dependent, at least partially, on mTORC1
inhibition, which promotes autophagic degradation of dysfunctional mitochondria or an Nrf2 inhibi-
tor Keap1 (Bae et al, 2013; Lee et al, 2010; Woo et al, 2009). However, Sestrin can also function
as an active oxidoreductase that can directly detoxify ROS such as alkylhydroperoxides (Kim et al,
2015a). Sestrins inhibit mTORC1 through the activation of AMP-activated protein kinase (AMPK)
and the subsequent inactivation of Rheb GTPases (Budanov and Karin, 2008; Sanli et al, 2012).
Independently of AMPK, Sestrins can also inhibit Rag GTPases (Chantranupong et al, 2014;
Kim et al, 2015b; Parmigiani et al, 2014; Peng et al, 2014), which are essential for mTORC1 activ-
ity. Sestrin-mediated inhibition of mTORC1 is also critical for limiting protein synthesis upon
unfolded protein accumulation (Bruning et al, 2013; Park et al, 2014) or amino acid starvation
(Peng et al, 2014; Wolfson et al, 2015; Ye et al, 2015), thereby suppressing ER stress or nutrient
crisis.
In light of these important cellular functions, the present study assessed if Sestrin functions as a
coordinator of mTORC1 and ER stress signaling pathways in the colon during intestinal inflammation
and carcinogenesis. Our data collected from patient samples, mouse models of colitis and colitis-
associated cancer, cultured colon cancer cell lines as well as data mining of large-scale transcriptome
analyses, concertedly indicate that Sestrin2, a member of the Sestrin family, is important for proper
regulation of mTORC1 and ER stress pathways during colon injury, and thereby functions as a sup-
pressor of colitis and colon cancer development.
eLife digest An organ that is inflamed has an increased risk of developing cancer. Inflammation
can be elicited in various ways; and intestinal inflammation and colon cancer development are often
associated with a protein complex – called mTORC1 – being overactive in the tissue. This protein
complex has been studied in other contexts and is known to instruct cells to produce more proteins.
However, when too much protein is made too quickly, cells cannot carry out their routine quality
checks. This, in turn, can lead to unfolded proteins accumulating in the cell, which is stressful and
damaging, and can cause inflammation. Increased production of proteins and other biomolecules
can also allow the uncontrolled growth of cancer cells.
Other recently discovered proteins – called sestrins – can counteract the cancer-promoting
effects of overactive mTORC1. Sestrins achieve this via several mechanisms, but as yet almost
nobody had studied the role of these proteins in intestinal inflammation and colon cancer.
Ro, Xue et al. deleted the genes for two members of the sestrin family, called Sestrin2 and
Sestrin3, in mice and showed that their colons were more prone to inflammation. Additional analysis
showed that people with ulcerative colitis – a condition in which the colon is chronically inflamed –
have elevated levels of Sestrin2, whereas very low levels of Sestrin2 could be detected in tissue
samples from patients with colon cancers. These data suggested that Sestrin2 might be trying to
protect cells from injury and acts as a barrier to cancer formation.
Ro, Xue et al. then used biochemical techniques in human cancer cells grown in the laboratory to
show that Sestrin2 inhibits mTORC1, making these cells grow less. Colon cancer cells with little or
no Sestrin2 were also more resistant to chemotherapy than control cells with normal levels of
Sestrin2. Lastly, a type of colon cancer that is associated with inflammation grew faster in mice that
lacked the gene for Sestrin2. Taken together these findings represent evidence that Sestrin2 acts as
a tumor suppressor in the colon. Future experiments might investigate how losing Sestrin2 makes
these cells more resistant to chemotherapy and whether sestrins act as tumor suppressors in other
tissues as well.
DOI: 10.7554/eLife.12204.002
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Results
Loss of Sestrin2 sensitizes mice to colon injury
Increased ER stress and excessive ROS accumulation are hallmarks of colon inflammation and colitis
(Fritz et al, 2011; Zhu and Li, 2012). Sestrins can be induced upon either of these stresses and are
critical to dampen their detrimental consequences (Bruning et al, 2013; Lee et al, 2013; Park et al,
2014). Therefore, to understand the role of Sestrins in colitis, expression of Sestrins was analyzed in
tissues isolated from patients with ulcerative colitis (UC). Sestrin1 mRNA (SESN1) was unaltered in
UC (Figure 1A); however, expression of SESN2 (Figure 1B) and SESN3 (Figure 1C) was significantly
increased in the intestine of patients with UC.
To examine whether colitis-induced Sestrin2 and Sestrin3 play a physiological role in maintaining
intestinal homeostasis, WT and Sesn2-/-/Sesn3-/- mice were treated with dextran sulfate sodium
(DSS) in the drinking water to induce colitis. DSS treatment for 7 days led to substantial weight loss
in both WT and Sesn2-/-/Sesn3-/- mice (Figure 1—figure supplement 1A). After placing back on reg-
ular water, WT mice recovered their body weight (Figure 1—figure supplement 1A). However,
Sesn2-/-/Sesn3-/- mice did not show any recovery and continued to lose body weight until the experi-
mental endpoint (5 days during the recovery phase; Figure 1—figure supplement 1A). Sesn2-/-/
Sesn3-/- mice also showed a dramatic decrease in colon length when compared to WT mice (Fig-
ure 1—figure supplement 1B), indicative of strongly exacerbated DSS-induced colitis. Histological
examination of colon tissue sections also revealed significant epithelial degeneration in Sesn2-/-/
Sesn3-/- mice following the 5 days of recovery from the 7-day DSS treatment, while WT mice exhib-
ited substantial regeneration of epithelial structure at the same time point (Figure 1—figure supple-
ment 1C). The increased susceptibility of Sesn2-/-/Sesn3-/- mice to DSS-induced injury (Figure 1—
figure supplement 1A–C) was recapitulated in Sesn2-/- mice; although both WT and Sesn2-/- mice
develop severe colitis with one week of DSS treatment (Figure 1D and Figure 1—figure supple-
ment 2), WT mice successfully recovered from injury after one additional week of regular water
treatment, while Sesn2-/- mice did not (Figure 1D–F). These results demonstrate a critical role for
Sestrin2 in restoring intestinal homeostasis after injury.
Sestrin2-deficient mice fail to recover from DSS-induced colitis
We examined molecular markers for cell death and inflammation in the colons of WT, Sesn2-/- and
Sesn2-/-/Sesn3-/- mice after DSS treatment. At 5 days after DSS injury, WT mice displayed a very
small number of apoptotic cells (Figure 1G and Figure 1—figure supplement 1D), consistent with
the histological observation showing that the colon epithelium had been restored (Figure 1F and
Figure 1—figure supplement 1C). However, a significant number of apoptotic cells were observed
in the colon epithelium of both Sesn2-/- and Sesn2-/-/Sesn3-/- mice (Figure 1G and Figure 1—figure
supplement 1D), consistent with the degenerative phenotypes observed in these mice. Proliferating
cell nuclear antigen (PCNA) staining of WT colon displayed a normal pattern of cell proliferation;
PCNA staining is confined to the base of colon crypts in WT mice (Figure 1H and Figure 1—figure
supplement 1E), where epithelial progenitor cells are undergoing homeostatic proliferation that
maintains normal turnover of the epithelium. However, the colon epithelium of both Sesn2-/- and
Sesn2-/-/Sesn3-/- mice exhibited an increased number of PCNA-positive cells throughout the degen-
erated epithelium (Figure 1H and Figure 1—figure supplement 1E). This result suggests that, in
order to compensate for the apoptotic loss of epithelial cells, colonocytes of both Sesn2-/- and
Sesn2-/-/Sesn3-/- mice were undergoing active proliferation. Immunohistochemical staining of macro-
phage marker F4/80 (Figure 1I and Figure 1—figure supplement 1F), as well as quantitative RT-
PCR examination of inflammation markers Tnfa (Figure 1J), Il6 (Figure 1K), Il1b (Figure 1L) and Il10
(Figure 1M), show that Sesn2-/- mice had increased the levels of colon inflammation after DSS injury.
These data collectively indicate that Sestrin2 deficiency exacerbates DSS-induced colon damage and
inflammation.
Sestrin2 expression in the extra-hematopoietic compartment
suppresses colitis
Inflammatory cytokine signaling instigated by bone marrow-derived immune cells, such as macro-
phages, is known to be important for the progression of colitis as well as colon cancer (Terzic et al,
Ro et al. eLife 2016;5:e12204. DOI: 10.7554/eLife.12204 3 of 20
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2010). We examined whether the expression of Sestrin2 in the bone marrow-derived hematopoietic
compartment is important for the protective role of Sestrin2 in colitis. For this purpose, reciprocal
bone marrow chimera experiments were performed: WT bone marrow was introduced into lethally
irradiated Sesn2-/- mice (WTfiSn2) while Sesn2-/- bone marrow was introduced into lethally
Figure 1. Protective function of Sestrin2 against colon injury. (A-C) Upregulation of human SESN2 and SESN3 expression in ulcerative colitis (UC).
mRNA expression of human SESN1-3 was analyzed through quantitative RT-PCR of non-inflamed (Normal) and inflamed (UC) colon tissues from
patients with UC (n=10; mean ± s.e.m.). These samples were histologically confirmed and formerly described (Xue et al, 2013). (D-M) Loss of Sestrin2
impairs recovery from DSS-induced colitis in mice. 6-month-old WT and Sesn2-/- mice (n=4 each) were treated with 3% DSS in drinking water for 6 days
(arrows), followed by 6 days of regular water. Body weight was measured over 12 days (D; mean ± s.e.m.). At the final day of the experiment, mice were
sacrificed and colon length was measured (E). The data are shown as the mean ± s.e.m. The colons were isolated and fixed for H&E staining (F), TUNEL
staining (G), PCNA staining (H) and F4/80 staining (I). The levels of the indicated mRNAs, which are indicative of active inflammation, were quantified by
real-time PCR (J-M; mean ± s.e.m.). *p<0.05, **p<0.01, ***p<0.001. P values are from Student’s t-test. Scale bars, 100 mm.
DOI: 10.7554/eLife.12204.003
The following figure supplements are available for figure 1:
Figure supplement 1. Hypersensitivity of Sesn2-/-/Sesn3-/- mice against DSS-induced colon injury.
DOI: 10.7554/eLife.12204.004
Figure supplement 2. Acute colon injury is comparable between WT and Sesn2-/- mice during DSS treatment.
DOI: 10.7554/eLife.12204.005
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irradiated WT mice (Sn2fiWT). Both groups of chimeric mice were subjected to DSS administration
(Figure 2A). Interestingly, Sn2fiWT mice were similar to WT mice and able to recover from DSS-
induced injury (Figure 2A,B). However, more than 70% of WTfiSn2 mice were dead at 6 days fol-
lowing DSS treatment (Figure 2B). WTfiSn2 mice, but not Sn2fiWT mice, also experienced dra-
matic weight loss during the recovery phase following DSS treatment (Figure 2A). Histological
examination of the surviving mice revealed that, although the epithelial structure of Sn2fiWT mouse
colon was nearly completely restored at 6 days after the DSS treatment, WTfiSn2 colon epithelium
was degenerated and marked by complete loss of epithelial cells and a robust increase in infiltrating
immune cells (Figure 2C). Genotyping of spleen tissues in surviving WTfiSn2 and Sn2fiWT mice
confirmed that the hematopoietic compartment of recipient mice had been completely substituted
with bone marrow cells of the donor (Figure 2D). These results indicate that the extra-hematopoietic
presence of Sestrin2, such as in epithelial cells, is critical for the maintenance of intestinal homeosta-
sis during colitis.
Sestrin2 deficiency impairs recovery from DSS-induced ER stress
Sestrin2 protects cells and tissues from ER stress and its pathological sequelae such as metabolic
abnormalities, tissue inflammation and apoptotic cell death (Park et al, 2014). DSS treatment was
recently found to induce ER stress in colon epithelia (Cao et al, 2013), and consistent with this
report, we observed that DSS treatment can induce prolonged ER stress signaling that is associated
with modestly elevated Sestrin2 expression (Figure 2—figure supplement 1). Therefore, it is possi-
ble that Sestrin2 protects colon epithelium by allowing colonocytes to cope with DSS-induced ER
Figure 2. Sestrin2 prevents colitis-associated ER stress in colonic epithelia. (A-D) Sestrin2 expression in the extra-hematopoietic compartment is critical
for the resolution of DSS-induced colitis. 3-month-old WT and Sesn2-/- mice (n=7 each) were subjected to lethal irradiation and injected with bone
marrow cells from age-matched Sesn2-/- (Sn2fiWT) and WT (WTfiSn2) mice, respectively. After 1 month, mice were subjected to DSS administration as
indicated in the panel A. Body weight was measured over 15 days (A). Data are shown as mean ± s.e.m. Percent survival was calculated for each day (B).
The colons of surviving mice at the final day of experiment were isolated and fixed for H&E staining (C). The spleens of surviving mice were genotyped
for WT (upper band, ~450bp) and Sesn2-KO (lower band, ~200bp) alleles (D). (E-H) Loss of Sesn2 aggravates colitis-induced ER stress in colon.
Expression or phosphorylation of ER stress signaling markers were analyzed from indicated mice (described in Figure 1D-M) through immunoblotting
(E), real-time PCR (F) or immunohistochemistry (G,H). Data are shown as mean ± s.e.m. *p<0.05, **p<0.01. P values are from Student’s t-test. Scale bars,
200 mm (black), 100 mm (white). Molecular weight markers are indicated in bp (D) or kDa (E).
DOI: 10.7554/eLife.12204.006
The following figure supplements are available for figure 2:
Figure supplement 1. Induction of ER stress and Sestrin2 upon DSS treatment.
DOI: 10.7554/eLife.12204.007
Figure supplement 2. Increased ER stress in colon epithelia of Sesn2-/- and Sesn2-/-/Sesn3-/- mice during DSS-induced colon injury.
DOI: 10.7554/eLife.12204.008
Figure supplement 3. Uncropped images of blots.
DOI: 10.7554/eLife.12204.009
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stress insults, and thereby promoting colonic recovery after DSS injury. To test this idea, we analyzed
the level of ER stress in WT and Sesn2-/- colon epithelium recovering from DSS injury. Immunoblot
analyses of colon tissue showed that Sesn2-/- and Sesn2-/-/Sesn3-/- mice have elevated phosphoryla-
tion of pancreatic ER kinase (PERK) and increased expression of BiP and CHOP (Figure 2E and Fig-
ure 2—figure supplement 2A,B), when compared to WT mice. mRNA expression analysis for ER
stress target genes, including spliced XBP1 (XBP1s) and BiP cofactor ERdj4, were also robustly upre-
gulated in the colon of Sesn2-/- mice (Figure 2F and Figure 2—figure supplement 2C). Immunos-
taining of BiP and CHOP also confirmed the presence of prominent ER stress in the damaged colon
epithelium of Sesn2-/- mice (Figure 2G,H and Figure 2—figure supplement 2D,E). These results col-
lectively indicate that endogenous Sestrin2 is critical for the suppression of colon ER stress after DSS
insults.
Figure 3. Downregulation of SESN2 in human colon cancer tissues. (A) Oncomine analysis of Sestrin-family gene expression in normal and cancer
tissues of different types. Gene summary views for SESN2, SESN1 and SESN3 genes are shown. Cell color is determined by the best gene rank
percentile for the analyses within the cell, as described below the table. Thresholds for gene rank, fold change and P value are also described below
the table. Reduction of SESN2 in colorectal cancer tissue (highlighted in the green box) was one of the most significant alterations. (B-G) human SESN2
mRNA expression in normal colon and colon cancer tissues, derived from six independent studies (B-G; total n=40, 78, 58, 82, 80 and 165, respectively)
conducted in different platforms (Gaspar et al, 2008; Graudens et al, 2006; Hong et al, 2010; Kaiser et al, 2007; Cancer Genome Atlas Network,
2012; Skrzypczak et al, 2010). (H) DNA copy number analysis of human SESN2 gene in normal blood, normal colon and colon cancer tissues
(total n=975), derived from TCGA dataset (Cancer Genome Atlas Network, 2012). Colon cancer staging in F, G and H is according to the TNM
staging system from the American Joint Committee on Cancer (AJCC). All data are shown as the mean ± s.e.m. P values between normal and cancer
tissues, calculated from Student’s t-test, are all below 10–4 (B-H). For TCGA dataset, P values between normal and cancer tissues are 1.6 x 10–30 (G) and
3.7 x 10–58 (H).
DOI: 10.7554/eLife.12204.010
The following figure supplement is available for figure 3:
Figure supplement 1. Expression of cell-type specific markers in human colon cancer tissues.
DOI: 10.7554/eLife.12204.011
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Downregulation of SESN2 in human cancer tissues
Our results show that Sestrin2 expression is induced during UC as a protective mechanism against
colonic ER stress and epithelial degeneration. Since pre-existing colitis (Terzic et al, 2010) or tumor-
elicited inflammation (Grivennikov et al, 2012) is important for the progression of colon cancer, it is
possible that Sestrin2 expression is lost or downregulated during colon carcinogenesis. Thus, we
examined the Oncomine database, which contains diverse large-scale genomic and transcriptomic
analyses of normal and tumor tissues (Rhodes et al, 2007), to determine if there is a differential
expression of Sestrins between normal and tumor tissues. Surprisingly, in virtually all of the colon
cancer transcriptome studies available within the database, which were conducted in diverse plat-
forms using different patient tissues, human Sestrin2 (SESN2) mRNA expression was strongly down-
regulated in colon adenocarcinoma tissues when compared to normal colon controls (Figure 3A–G)
(Gaspar et al, 2008; Graudens et al, 2006; Hong et al, 2010; Kaiser et al, 2007; Cancer Genome
Atlas Network, 2012; Skrzypczak et al, 2010). The magnitude of SESN2 suppression in tumors is
often among the top 1–5% of all suppressed genes (Figure 3A). Considering that these data are col-
lected from a variety of different human samples, the extent of the difference was very strong (all
studies indicate p<10–4 or much lower). In contrast, other major cell type markers, such as Villin
(VIL1, enterocytes), DLL1 (progenitor cells), F4/80 (EMR1, macrophages), Gr-1 (LY6G5B, leukocytes),
or b-catenin (CTNNB, colon epithelia), did not show such strong suppression (Figure 3—figure sup-
plement 1A–E), while the stem cell marker LGR5 was rather upregulated in tumor samples
Figure 4. Correlation between p53 status and SESN2 expression in human colon cancer. TCGA colon/colon cancer dataset (total n=165) was
partitioned according to the p53 status (Cancer Genome Atlas Network, 2012). Normal colon tissues do not reveal any TP53 mutation (n=19 in the
dataset), while ~43% of tumor samples in the gene expression dataset (n=63 out of total 146 tumor samples), designated as ’p53-mutated’, identified
missense or nonsense point mutations in the TP53 coding region. Other tumor samples (n=83) are designated as ’p53-unknown’. (A) SESN2 expression
was analyzed in indicated tissues. Data are shown as the mean ± s.e.m. **p<0.01,***p<0.001. P values were calculated from Student’s t-test. (B,C)
Expression of SESN2 was analyzed in three different probes, and their correlations were visualized by a scatter plot of individual patient tissue samples.
Trend lines were approximated through linear regression. Y axis is in a log scale. Normal colon samples are in blue, ’p53-unknown’ tumor samples are
in gray, and ’p53-mutated’ tumor samples are in red. Pearson’s correlation coefficients (r) with P values were calculated and presented. ****p<0.0001.
(D-F) Expression of SESN2, CDKN1A, GADD45A and MDM2 was analyzed and their correlations were analyzed as described above for B and C.
**p<0.01, ***p<0.001, ****p<0.0001.
DOI: 10.7554/eLife.12204.012
The following figure supplement is available for figure 4:
Figure supplement 1. Correlation between p53 status and expression of CDKN1A, GADD45A, MDM2, BAX, PUMA (BBC3), p53AIP1 (TP53AIP1), TSC2,
AMPKb (PRKAB1, PRKAB2) and PTEN in human colon cancer.
DOI: 10.7554/eLife.12204.013
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(Figure 3—figure supplement 1A–E). These results indicate that the downregulation of SESN2
mRNA in colon cancer is specific and not an indirect consequence of different compositions of cell
subtypes between normal and tumor tissues.
SESN2 genome copy is also significantly reduced in colon cancer, and decreases further as the
colon cancer progresses (Figure 3H). However, the extent of copy number loss was very small
(~10%), suggesting that transcriptional downregulation, rather than the loss of genomic information,
is the major mechanism of SESN2 inhibition during colon cancer progression.
SESN2 expression exhibits strong correlation with p53 status
SESN2 is a transcriptional target of tumor suppressor p53 (Budanov et al, 2002), which is one of the
most frequently mutated genes in colon cancer (Fearon, 2011). To test whether p53 mutation plays
any role in regulating SESN2 expression during colon carcinogenesis, we analyzed the cancer
genome atlas (TCGA) dataset (Cancer Genome Atlas Network, 2012) by partitioning tumors based
on p53 status. TCGA dataset has comprehensive information regarding the genomic status of each
tumor, determined by whole genome/exome sequencing. From this database, we were able to clas-
sify all the colon tumor samples into the two groups. One group, designated as ’p53-mutated’, has
one or more missense or nonsense coding sequence mutations in the TP53 gene. The second group,
designated as ’p53-unknown’, is classified as such because it does not reveal any coding sequence
mutations in the TP53 gene; however, it is still possible that these tumors contain TP53 mutations in
Figure 5. Loss of Sesn2 promotes colon tumor growth in mice. (A) 2-month-old WT and Sesn2-/- mice were exposed to a standard protocol of
azoxymethane (AOM)-dextran sulfate sodium (DSS)-induced colon carcinogenesis as outlined in this figure panel. However, none of the Sesn2-/- mice
(n=7) survived after the first round of administration of DSS , suggesting that they are hypersensitive to DSS-induced colitis. (B) WT and Sesn2-/- mice
(n=11 each) were subjected to a modified protocol of AOM-DSS-induced colon cancer. By reducing the dose of DSS to 1.5%, we were able to keep a
substantial number of Sesn2-/- mice (n=9) alive until the experimental endpoint. Tumor incubation period was extended to 100 days to compensate for
the lower dose of DSS treatment. (C-G) After completion of the experiment, colons were examined under a dissection microscope (C), and tumor
number (D), average tumor size (E), size of individual tumors (F) and total tumor burden (G) were analyzed and presented as means from each mouse
and as mean ± s.d. of the whole groups. (H-N) Sestrin2-deficient tumors exhibit increased proliferation. Colon tumor (T) and normal colon (N) tissues of
indicated mice were subjected to immunohistochemistry of b-catenin (H), PCNA (I) and g-H2AX (J) or TUNEL staining (K). PCNA- (L), g-H2AX- (M) and
TUNEL-positive (N) cells from indicated tissues were quantified and presented as mean ± s.e.m. NS, not significant; *p<0.05, **p<0.01, ***p<0.001. P
values are from Student’s t-test. Scale bars, 100 mm.
DOI: 10.7554/eLife.12204.014
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essential non-coding regions (e.g. promoters, enhancers or introns) or other genomic or epigenetic
alterations that can lead to functional p53 inactivation (e.g. MDM2 overexpression). Expressions of
SESN2 and other known p53 target genes were then analyzed in three different groups: normal
colons, ’p53-unknown’ tumors and ’p53-mutated’ tumors (Figure 4 and Figure 4—figure supple-
ment 1).
The analyses demonstrated that SESN2 expression is significantly reduced in ’p53-mutated’
tumors when compared to ’p53-unknown’ tumors (Figure 4A), suggesting a role of p53 in control-
ling SESN2 expression. This reduction was consistently observed in three independent SESN2
probes (Figure 4A–C). Strikingly, there were almost no overlaps of SESN2 expression levels between
the normal colon and ’p53-mutated’ tumor groups (Figure 4B,C), while SESN2 levels in ’p53-
Figure 6. Sestrin2 loss increases mTORC1 signaling in colon cancer. (A-D) 3-month-old WT and Sesn2-/- mice (n=11 each) were subjected to lethal
irradiation and injected with bone marrow cells from age-matched Sesn2-/- (Sn2fiWT) and WT (WTfiSn2) mice, respectively. After 1 month, mice were
subjected to AOM/DSS administration as indicated in Figure 5B. After completion of the experiment, colons were examined under a dissection
microscope (A), and tumor number (B), colon length (C) and tumor size (D) were analyzed and presented as mean ± s.e.m. (E, F and J) Colon tumor (T)
and normal colon (N) tissues of indicated mice were subjected to immunohistochemistry of phospho-Ser235/236-S6 (E and J) or phospho-Thr37/46-4E-
BP (F). (G-I, K and L) Colon tumor (T) and normal colon (NT) tissues of WT and Sesn2-/- (S2) mice (G-I), as well as WTfiSn2 and Sn2fiWT mice (K and L),
were subjected to immunoblotting of indicated mTORC1 and mTORC2 signaling markers (G and K). Relative band intensities were quantified through
densitometry and presented as mean ± s.e.m (H, I and L; n=6 in each group). *p<0.05, ***p<0.001. P values are from Student’s t-test. Scale bars, 200
mm. Molecular weight markers are indicated in kDa.
DOI: 10.7554/eLife.12204.015
The following figure supplements are available for figure 6:
Figure supplement 1. Efficiency of bone marrow transplantation.
DOI: 10.7554/eLife.12204.016
Figure supplement 2. Additional immunohistochemistry results for Figure 6E (A), Figure 6F (B) and Figure 6J (C).
DOI: 10.7554/eLife.12204.017
Figure supplement 3. Additional immunoblotting results for Figure 6G (A) and Figure 6K (B).
DOI: 10.7554/eLife.12204.018
Figure supplement 4. Uncropped images of blots.
DOI: 10.7554/eLife.12204.019
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unknown’ tumors overlap with both groups (Figure 4B,C). Other known p53 target genes, such as
CDKN1A (p21), GADD45A and MDM2 (Riley et al, 2008), did not show this strong correlation: for
these genes, considerable overlaps were found between the normal colon and ’p53-mutated’ tumor
groups in individual samples (Figure 4D–F). Nevertheless, expression levels of these genes have a
general positive correlation with expression of SESN2 in individual samples (Figure 4D–F), suggest-
ing that SESN2, CDKN1A, GADD45A and MDM2 are all regulated through the same p53-dependent
mechanism. Indeed, all of these genes are differentially expressed between ’p53-unknown’ and
’p53-mutated’ tumor groups (Figure 4A and Figure 4—figure supplement 1A–C).
Figure 7. p53 controls mTORC1 signaling through Sestrin2 in colon cancer cells. (A-F) Whole cell or tissue lysates from the following experiments were
subjected to immunoblotting of indicated proteins. (A) Human colon cancer cell lines (RKO, HCT116 and SW480) were serum-starved for 24 hr and then
treated with 10% FBS (serum) for 2 hr. (B) p53-knockout (HCT116 p53-/-) and control HCT116 cells were serum-starved for 24 hr and then treated with
10% FBS for indicated time. (C) CDX2P-CreERT2Apcflox/flox KrasLSL-G12D/+ p53flox/flox (left three lanes), CDX2P-CreERT2Apcflox/flox KrasLSL-G12D/+ p53+/+
(centre three lanes), and CDX2P-CreERT2Apcflox/flox KrasLSL-G12D/+ p53R270H/+ (right three lanes) mice (Feng et al, 2013) were daily injected with 100 mg/
kg tamoxifen (i.p.) for 3 days, and dysplastic colon tissues were harvested after 8 days. (D) HCT116 p53-/- cells were infected with GFP- or Sestrin2-
expressing lentiviruses. After 24 hr, cells were serum-starved for 24 hr and treated with 10% FBS for indicated time. (E) SW480 cells were infected with
GFP- or Sestrin2-expressing lentiviruses. After 24 hr, cells were serum-starved for 24 hr and treated with 10% FBS for indicated time. (F) RKO cells,
stably infected with lentiviruses expressing shRNA targeting luciferase (sh-Luc) or the SESN2 (sh-SESN2) gene, were serum-starved for 24 hr and then
treated with 10% FBS for indicated time. Molecular weight markers are indicated in kDa.
DOI: 10.7554/eLife.12204.020
The following figure supplements are available for figure 7:
Figure supplement 1. Sestrin2 inhibits colon cancer cell growth through mTORC1 inhibition.
DOI: 10.7554/eLife.12204.021
Figure supplement 2. Sestrin2-deficiency renders cancer cells less sensitive to chemotherapy.
DOI: 10.7554/eLife.12204.022
Figure supplement 3. Uncropped images of blots.
DOI: 10.7554/eLife.12204.023
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Interestingly, some p53 target genes, such as apoptosis mediators BAX, PUMA (BBC3) and
p53AIP1 (TP53AIP1) (Riley et al, 2008) or mTORC1 regulators TSC2, AMPKb (PRKAB1 and PRKAB2)
and PTEN (Feng et al, 2007), did not show differential expression between the ’p53-unknown’ and
’p53-mutated’ tumor groups (Figure 4—figure supplement 1D–J), suggesting that the effects of
p53 mutations on these genes are minimal in the pathological context of colon carcinogenesis.
These results collectively highlight SESN2 as a clinically relevant target of p53 during colon
carcinogenesis.
Sesn2 loss promotes colitis-induced colon cancer growth
To more precisely establish the cause-effect relationship between Sestrin2 and colon cancer devel-
opment, Sesn2-/- mice were further assessed. The analysis of two-year-old WT and Sesn2-/- mice
(n=6 each) did not reveal any noticeable colon tumors, suggesting that Sesn2 may not be a classical
tumor suppressor gene whose homozygous deletion is sufficient to induce spontaneous cancer
development. However, given the strong correlation between SESN2 expression and colon cancer
tumorigenesis in humans (Figure 3), we reasoned that endogenous Sestrin2 may play a role in atten-
uating tumor development and progression. Thus, Sesn2-/- mice were subjected to an established
protocol of colitis-associated colon cancer induction; in this model, colon carcinogenesis is initiated
by azoxymethane (AOM) administration and promoted by repeated colon injury induced by 2.5%
DSS. However, none of Sesn2-/- mice (n=7) survived the first round of colitis induction (Figure 5A),
while WT mice were able to survive the entirety of the treatment. This is consistent with our findings
that Sestrin2 has an important physiological role in maintaining epithelial integrity during colon injury
(Figures 1–2).
To overcome the DSS-induced lethality of Sesn2-/- mice, a lower dose of DSS (1.5%) was adminis-
tered to both control and experimental groups in the colitis-associated cancer model (Figure 5B).
This modification enabled both WT and Sesn2-/- groups to survive through three inflammatory and
recovery phases, and develop macroscopically visible colon tumors at 100 days after AOM injection
(Figure 5C). There was no substantial difference in the number of tumors between WT and Sesn2-/-
mice (Figure 5D). However, tumor size (Figure 5E,F) and burden (Figure 5G) were dramatically
increased in Sesn2-/- mice, suggesting that Sestrin2 loss promoted tumor growth and progression in
the colitis-associated cancer model. Tumors developed in both WT and Sesn2-/- mice displayed clas-
sical characteristics of colon adenomas, such as nuclear b-catenin staining (Figure 5H), increased cell
proliferation (Figure 5I; PCNA staining), DNA damage (Figure 5J; g-H2AX staining) and apoptotic
cell death (Figure 5K; TUNEL staining). Quantification of PCNA-, g-H2AX- and TUNEL-positive cells
showed that tumor cell proliferation (Figure 5L) is significantly increased in tumors isolated from
Sesn2-/- mice, while DNA damage (Figure 5M) and apoptosis (Figure 5N) were not significantly
altered by the loss of Sestrin2.
Sestrin2 suppresses tumor growth in the extra-hematopoietic
compartment
Using the reciprocal bone marrow chimera experiments followed by the AOM-DSS treatments (Fig-
ure 6—figure supplement 1), we assessed whether the expression of Sestrin2 in the hematopoietic
or extra-hematopoietic compartment is important for the tumor-suppressive role of Sestrin2 in colon
cancer. Compared to the Sn2fiWT mice, WTfiSn2 mice exhibited strongly exacerbated tumor
growth phenotypes, which was evident in both tumor number and size (Figure 6A–D), indicating
that the extra-hematopoietic expression of Sestrin2, such as in colon epithelia, is critical for colon
tumor suppression.
Sesn2 loss induces mTORC1 hyperactivation
It is possible that epithelial Sestrin2 expression tissue-autonomously suppresses colon tumor growth.
Indeed, Sestrin2 is a potent inhibitor of mTORC1 (Budanov and Karin, 2008; Lee et al, 2013),
which is known to be critical for tumorigenic growth in colon cancer cells (Faller et al, 2015;
Hardiman et al, 2014). Therefore, we analyzed mTORC1 downstream target proteins in colon can-
cer and normal colon tissues from WT and Sesn2-/- mice through immunohistochemistry. Phosphory-
lation of ribosomal protein S6, which is mediated by an mTORC1 target p70 S6 kinase (S6K), is
dramatically increased in tumors isolated from Sesn2-/- mice (Figure 6E and Figure 6—figure
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supplement 2A). Consistent with this observation, phosphorylation of eukaryotic translation initia-
tion factor 4E-binding protein (4E-BP), an additional mTORC1 target, was also prominently increased
in Sesn2-/- colon cancer tissues, when compared to adjacent normal colon tissues as well as to WT
colon cancer tissues (Figure 6F and Figure 6—figure supplement 2B). These immunohistochemical
observations were also confirmed by immunoblotting experiments; S6 and 4E-BP phosphorylation
was prominently increased in colon tumors of Sesn2-/- mice, compared to those of WT mice
(Figure 6G–I and Figure 6—figure supplement 3A). Tumors from WTfiSn2 mice, but not those
from Sn2fiWT mice, also exhibited hyperactive mTORC1 signaling, indicated by increased S6 phos-
phorylation (Figure 6J–L and Figure 6—figure supplement 2C,3B). However, AKT Ser473 phos-
phorylation, which is mediated by mTORC2, a complex distinct from mTORC1, was not significantly
altered by Sestrin2 loss in colon cancer tissues (Figure 6G). Collectively, these data suggest that Ses-
trin2 loss selectively leads to mTORC1 hyperactivation in colon cancer tissues, which subsequently
allowed for prominent tumor overgrowth.
p53 regulates Sestrin2 expression in colon cancer cells
Unlike human colon cancer tissues (Figures 3,4), mouse colon cancers induced by the AOM-DSS
treatment displayed Sestrin2 expression at a level comparable to that of normal colon tissues
(Figure 6G). The expression of Sestrin2 in mouse colon tumor cells may provide an explanation for
the relatively low mTORC1 activity in the tumors (Figure 6E–L) that do not progress to adenocarci-
nomas (Rosenberg et al, 2009). Interestingly, it has been formerly reported that most mouse colon
tumors induced by the AOM-DSS treatment do not contain p53 mutations or misregulation
(Nambiar et al, 2004; Takahashi and Wakabayashi, 2004), and this may provide an explanation of
why Sestrin2 expression is sustained in this specific mouse model of colon cancer. Indeed, SW480
cells, a human colon cancer cell line that displays very low p53 activity, demonstrated a strong down-
regulation of Sestrin2 expression, while RKO and HCT116 cells, which have wild-type p53 activity,
expressed a relatively high amount of Sestrin2 proteins (Figure 7A). The p53-deficient HCT116 cells
exhibited dramatic downregulation of Sestrin2 expression when compared to the parental HCT116
cells (Figure 7B). Expression of Sestrin2 in hyperplastic mouse colon tissues, which have mutations in
both Apc and Kras genes (Feng et al, 2013), was also reduced by the loss of p53 or a dominant-
negative mutation of p53 (Figure 7C). Consistent with clinical data on human SESN2 expression
described above (Figure 4), these results further support the notion that p53 is critical for Sestrin2
expression in colon cancer cells.
Sestrin2 suppresses clonogenic growth through mTORC1 inhibition
p53 inhibits mTORC1 signaling, and this regulation may be an important contributor to the tumor
suppressive activity of p53 (Agarwal et al, 2016; Feng and Levine, 2010). To understand if Sestrin2,
acting as a p53 target, has an essential role in regulating mTORC1 and colon cancer cell growth,
Sestrin2 was overexpressed in p53-deficient HCT116 cells and SW480 cells, which have low SESN2
expression and high mTORC1 signaling (Figure 7A,B). Restoration of Sestrin2 suppressed serum-
induced phosphorylation of mTORC1 substrates, S6K and 4E-BP (Figure 7D,E), but not mTORC2
substrate AKT (Figure 7E). Sestrin2 silencing in RKO cells enhanced the mTORC1 signaling in both
starved and serum-stimulated cells (Figure 7F), indicating that endogenous Sestrin2 indeed func-
tions to inhibit mTORC1 signaling in human colon cancer cells.
As mTORC1 is known to control cell growth, we examined the effect of Sestrin2 on clonogenic
growth of RKO and SW480 cells. A colony forming assay of Sestrin2-silenced RKO cells demon-
strated an increase in clonogenic growth compared to the control cells (Figure 7—figure supple-
ment 1A,B), suggesting that Sestrin2 is an inhibitor of cancer cell growth. To further investigate if
this Sestrin2 activity is dependent on mTORC1 hyperactivation, we treated control and Sestrin2-
silenced cells with rapamycin, an inhibitor of mTORC1. Rapamycin inhibited clonogenic growth in
both control and Sestrin2-silenced cells, and interestingly, the growth difference between control
and Sestrin2-silenced cells was diminished upon rapamycin treatment (Figure 7—figure supplement
1A,B). These results indicate that Sestrin2 attenuates cancer cell growth primarily through inhibition
of a hyperactive mTORC1. On the other hand, expression of Sestrin2 in SW480 cells substantially
inhibited clonogenic growth (Figure 7—figure supplement 1C,D), supporting the idea that Sestrin2
is critical for inhibition of colon cancer cell overgrowth.
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Sestrin2 loss confers chemotherapy resistance to colon cancer cells
As a stress-inducible cell growth regulator, Sestrin2 may be also important for the responsiveness of
colon cancer cells to chemotherapeutic treatments. To examine this possibility, we treated control
and Sestrin2-silenced RKO cells with two representative chemotherapeutic agents, 5-fluorouracil (5-
FU) and irinotecan (CPT-11). Although control cell growth was strongly suppressed by 5-FU or CPT-
11, Sestrin2 silencing rendered cells less susceptible to the chemotherapeutic drug treatments (Fig-
ure 7—figure supplement 2A–C), suggesting that Sestrin2 loss may confer chemotherapy resistance
to colon cancer cells.
We also examined Sestrin2 expression and mTORC1 signaling in RKO cells when treated with 5-
FU and CPT-11. After 5-FU or CPT-11 treatments, Sestrin2 expression was slightly elevated in WT
cells (sh-Luc; Figure 7—figure supplement 2D,E). Interestingly, mTORC1 signaling, monitored by
p-S6K and p-4E-BP1, was prominently upregulated in sh-SESN2 cells after 5-FU treatment (Fig-
ure 7—figure supplement 2D), suggesting that Sestrin2 suppresses mTORC1 activation after 5-FU
treatment. In contrast, CPT-11 treatment reduced mTORC1 signaling, and Sestrin2 silencing led to
modest but persistent mTORC1 upregulation (Figure 7—figure supplement 2E). This mTORC1
upregulation as a result of Sestrin2 loss could have conferred chemoresistance to RKO cells against
5-FU and CPT-11.
Discussion
The current study reveals how the stress-inducible protein Sestrin2 can coordinate ER stress and
mTORC1 signaling pathways to maintain epithelial homeostasis and limit colitis and colon cancer
development during colon injury (Figure 7—figure supplement 2F). Yet, it is still possible that the
mechanisms underlying increased susceptibility to colitis and colon cancer are separate from each
other. During colitis stress, Sestrin2 functions to suppress ER stress and to promote regeneration of
colon epithelium (Figures 1,2). However, Sestrin2 expression is lost during human colon carcinogen-
esis (Figure 3) through inactivation of tumor suppressor p53 (Figures 4,7). Because expression of
Sestrin2 is important for suppressing hyperactive mTORC1 signaling (Figure 6) and tumor outgrowth
(Figure 5), loss of Sestrin2 expression in human colon cancer serves as a critical tumorigenic mecha-
nism. Indeed, Sestrin2 negatively controlled cell growth in various human colon cancer cell lines,
which was dependent on mTORC1 regulation (Figure 7—figure supplement 1). Furthermore, inacti-
vation of Sestrin2 conferred chemoresistance to colon cancer cells (Figure 7—figure supplement 2),
rendering them difficult to treat with conventional chemotherapeutic methods.
In addition to mTORC1 regulation, Sestrin2 is also known to reduce oxidative stress
(Budanov et al, 2004) by functioning as an activator of anti-ROS transcription factor Nrf2 (Bae et al,
2013) or as an alkylhydroperoxidase (Kim et al, 2015a). Thus, it is possible that the loss of Sestrin2
can contribute to cellular accumulation of ROS, which can promote DNA damage and genomic
mutations that facilitate tumor development (Sablina et al, 2005). However, analysis of g-H2AX did
not show a significant increase in DNA damage between colon tumors of WT and Sesn2-/- mice
(Figure 5J,M). This result suggests that the mTORC1-regulatory function, rather than the ROS-inhib-
iting function, is the main contributor of Sestrin2’s tumor suppressive activity in colon tissues. Never-
theless, it is still possible that Sestrin2 attenuates tumor growth, at least partially by inhibiting
tumor-associated epithelial damage and inflammation (Figures 1,2), which are well-characterized
promoters of colon cancer growth (Grivennikov et al, 2012; Terzic et al, 2010). It is also possible
that Sestrin2 exerts tumor suppressive activity additionally through its apoptosis-inducing function,
which was recently discovered (Ding et al, 2015).
The mTORC1-suppressing and ROS-reducing activities are shared between all members of the
Sestrin family (Sestrin1-3) (Lee et al, 2013; Nogueira et al, 2008). However, only Sestrin2 was shown
to be downregulated in human colon cancer tissues, and expression of Sestrin1 and Sestrin3 was
unchanged or slightly upregulated in the colon cancer tissues. Nevertheless, Sestrin1 and Sestrin3
are strongly downregulated in several types of cancer tissues, such as lung cancers and lymphomas
(Figure 3A), suggesting that they may be involved in anti-tumorigenic processes in tissues other
than the colon. Drosophila Sestrin, which is the only Sestrin homologue expressed in Drosophila,
was formerly shown to be a feedback inhibitor of mTORC1, which can suppress hyperplastic tissue
growth provoked by oncogenic mTORC1 hyperactivation (Lee et al, 2010). As the current study
demonstrates Sestrin2 to be an inhibitor of colon cancer growth, future studies on the role of
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Sestrin1 and Sestrin3 in carcinogenic processes of other tissues may reveal a conserved tumor-sup-
pressive role of Sestrin-family proteins.
Materials and methods
Antibodies and reagents
For immunoblotting, we obtained S6K (sc-230), PERK (sc-13073) and p-PERK (sc-32577) antibodies
from Santa Cruz Biotechnology, Dallas, TX, human Sestrin2 (10795-1-AP) antibody from
Proteintech, Chicago, IL, BiP (3177), CHOP (2895), p-Thr389 S6K (9234), p-Ser235/236 S6 (2211), S6
(2317), p-Thr37/46 4E-BP (2855), 4E-BP (9452), p-Ser473 AKT (9273) and AKT (4691) antibodies from
Cell Signaling Technology, Danverse, MA, actin (JLA20) antibody from Developmental Studies
Hybridoma Bank (DSHB, Iowa city, IA), and tubulin (T5168) antibody from Sigma, St. Louis, MO.
Mouse Sestrin2 antibody was described (Ro et al, 2014b). For immunostaining, we obtained p53
(sc-6243), PCNA (sc-7907), b-catenin (sc-59737), CHOP (sc-575) from Santa Cruz Biotechnology, F4/
80 (mf48000) from Invitrogen, Carlsbad, CA, BiP (3177), g-H2AX (2577), p-Ser235/236 S6 (2211) and
p-Thr37/46 4E-BP (2855) from Cell Signaling Technology. Azoxymethane (AOM), dextran sulfate
sodium (DSS), rapamycin, 5-fluorouracil (5-FU) and irinotecan (CPT-11) were from Sigma.
Cell culture
Human colon cancer cell lines, including RKO, SW480 and HCT116, were obtained from American
Type Culture Collection (ATCC, Manassas, VA) and cultured in Dulbecco’s modified Eagle’s medium
(DMEM, Invitrogen) containing 10% fetal bovine serum (FBS, Sigma), 50 U/ml penicillin and 50 mg/
ml streptomycin. The cells were authenticated by Short Tandem Repeat (STR) profiling at ATCC,
tested negative for mycoplasma infection, and subcultured for less than 6 months prior to initiation
of the described experiments. p53-knockout HCT116 cells were obtained from Dr. Bert Vogelstein
(Johns Hopkins University, Baltimore, MD). The p53 loss in this cell line was confirmed by western
blot. All cultures were maintained in a 37˚C incubator with 5% CO2. The lentiviral constructs for Ses-
trin2 overexpression and silencing are formerly described (Budanov and Karin, 2008). Viruses were
generated and amplified in the Vector Core facility at the University of Michigan (UM).
Immunoblotting
Cells and tissues were lysed in RIPA buffer (50 mM Tris-Cl pH 7.4, 150 mM NaCl, 1% sodium deoxy-
cholate, 1% NP-40; 0.1% SDS) or cell lysis buffer (20 mM Tris-Cl pH 7.5, 150 mM NaCl, 1 mM EDTA,
1 mM EGTA, 2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate, 1 mM Na3VO4, 1% Triton-
X-100) containing protease inhibitor cocktail (Roche, Indianapolis, IA), and processed as formerly
described (Ro et al, 2014a). Protein samples were boiled in SDS sample buffer for 5 min, separated
by SDS-PAGE, transferred to PVDF membranes and probed with primary antibodies (1:200 for Santa
Cruz antibodies, and 1:1000 for all other antibodies). After incubation with secondary antibodies
conjugated with HRP (Bio-rad; 1:2000), chemiluminescence was detected using LAS4000
(GE, Fairfield, CT) systems or X-ray films. Immunoblot images were quantified by densitometry, and
protein expressions were presented as relative band intensities. Uncropped images of immunoblots
are provided in Figure 2—figure supplement 3, Figure 6—figure supplement 4 and Figure 7—fig-
ure supplement 3.
Quantitative reverse transcriptase-real time PCR
Total RNA was extracted from tissues or cells using Trizol reagent (Invitrogen), and cDNA was made
using MMLV-RT (Promega, Madison, WI) and random hexamers (Invitrogen). Quantitative PCR was
performed in a Real-Time PCR detection system (Applied Biosystems, Foster city, CA) with iQTM
SYBR Green Supermix (Bio-rad, Hercules, CA) and relevant primers. Relative mRNA expression was
calculated from the comparative threshold cycle (Ct) values relative to b-Actin. Primers for Sestrins,
inflammation markers (Tnfa, Il6, Il1b and Il10), ER stress markers (Xbp1s, ERdj4, Gadd34, Ero1a,
Edem1, and Pdi) and b-Actin were formerly described (Park et al, 2010; Park et al, 2014; Ro et al,
2014a).
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Database analyses
mRNA expression data and genome copy data from various studies were retrieved from Oncomine
database (Rhodes et al, 2007). Exome sequencing information regarding the status of p53 was
retrieved from Supplmentary Table 2 of TCGA colon cancer paper (Cancer Genome Atlas Network,
2012). TCGA data, retrieved from Oncomine, were manually partitioned into ’p53-mutated’ and
’p53-unknown’ groups according to the p53 gene status. When multiple probes for a same gene
were found from the database, probes whose average values between normal and cancer groups (or
between normal and ’p53-mutated’ groups) are close to zero in log scale were selected for further
analysis. Bar graphs were plotted in a linear scale and control values were normalized to one. Scatter
plots were presented in a logarithmic scale using raw data. Correlation and linear regression analy-
ses were performed in Graphpad Prism 6.
Animal experiments
WT, Sesn2-/- and Sesn2-/-/Sesn3-/- mice (Lee et al, 2012) and CDX2P-CreERT2Apcflox/floxmice
(Feng et al, 2013) were used for this study. These mice are on a C57BL/6 background. Mice were
maintained in filter-topped cages and given free access to autoclaved regular chow diet at the UM
according to the NIH and institutional guidelines. All animal studies were ethically approved (proto-
col approval numbers: PRO00005712 and PRO00004019) and overseen by the University Committee
on Use and Care of Animals (UCUCA) at the UM.
For colitis induction, mice received water with 3% DSS for 6–7 days (inflammatory phase). Then
the mice were placed on regular drinking water for 5–7 days (recovery phase) as formerly described
(Xue et al, 2013). For tumor induction, mice were treated with AOM (10 mg/kg body weight). At 5
days following the AOM injection, mice received water with 1.5% DSS for 7 days (inflammatory
phase). Then, the mice were placed on regular drinking water for 14 days (recovery phase). The mice
were subjected to two more inflammatory and recovery cycles for tumor induction as in Figure 5A,
B. Reciprocal bone marrow chimera experiments were done as described in our recent paper
(Anderson et al, 2013), and the mice were subjected to DSS or AOM/DSS treatment at 1 month
after the bone marrow transplantation to allow for complete substitution of the hematopoietic com-
partment. The mice in the same experiments are from an age-matched, co-housed cohort, and ani-
mal numbers were determined according to our previous studies (Anderson et al, 2013; Xue et al,
2013).
Colon tumor phenotyping
A dissecting microscope (4x magnification) was used to assess the tumor number and size. Tumor
size was defined as the mean of the two largest diameters measured with digital calipers. Tumor vol-
ume was derived from tumor size. Consistent with their histological appearance, a spherical shape
was assumed for colon polyps, thus tumor volume = 4/3pr3, where r = radius. Tumor burden/load is
defined as the total polyp volume per animal, which is the product of polyp number and polyp
volume.
Histology
Colons were removed, flushed with PBS, fixed in 4% paraformaldehyde at 4˚C overnight and paraf-
fin-embedded for histological analyses. Antigen retrieval was performed in 10 mM sodium citrate at
95˚C for 15 min. For immunostaining of PCNA, b-catenin, F4/80, BiP, g-H2AX, p-Ser235/236 S6 and
p-Thr37/46 4E-BP, colon sections were incubated with corresponding primary antibodies (1:50, 1:50,
1:100, 1:200, 1:50, 1:200 and 1:100, respectively), followed by incubation with biotin-conjugated sec-
ondary antibodies (1:200) and streptavidin-HRP (1:300). The HRP activity was visualized with diami-
nobenzidine staining. Haematoxylin counterstaining was applied to visualize nuclei. For
immunostaining of CHOP, colon sections were incubated with primary antibody (1:50), followed by
incubation with Alexa 594-conjugated secondary antibody. DAPI counterstaining was applied to
visualize nuclei. TdT-mediated dUTP nick end labeling (TUNEL) assay was performed using In Situ
Cell Death Detection Kit TMR-Red (1215792910, Roche). The samples were analysed under an epi-
fluorescence-equipped light microscope (Meiji MT6300).
Ro et al. eLife 2016;5:e12204. DOI: 10.7554/eLife.12204 15 of 20
Research article Cell biology Human biology and medicine
Acknowledgements
We thank Drs. M Karin (UCSD), AV Budanov (VCU), E Fearon, RA Miller, D Lombard, S Pletcher
(UM), and Santa Cruz Biotech Inc. for sharing reagents and access to lab equipment. We also thank
Jeongsoon Park for practical advice regarding clonogenic growth assay. This work was supported by
grants from the Ellison Medical Foundation (AG-NS-0932-12, to JHL), Crohn’s Colitis Foundation of
America (276556, to XX), American Gastroenterological Association (to XX) and NIH
(5T32GM008322 to A.H., CA148828 and DK095201 to YMS, DK102850 to JHL, and P30-AG024824,
P30-AG013283, P30-DK034933, P30-DK089503 and P30-CA046592).
Additional information
Funding
Funder Grant reference number Author
National Institutes of Health CA148828, DK095201,
DK102850, AG024824,
AG013283, DK034933,
DK089503, CA046592,
GM008322
Allison Ho
Yatrik M Shah
Jun Hee Lee
Lawrence Ellison Foundation AG-NS-0932-12 Jun Hee Lee
Crohn’s and Colitis Foundation
of America
276556 Xiang Xue
American Gastroenterological
Association
Xiang Xue
The funders had no role in study design, data collection and interpretation, or the decision to
submit the work for publication.
Author contributions
S-HR, Performed biochemical, histological and cell biological analyses, Acquisition of data, Analysis
and interpretation of data, Drafting or revising the article; XX, Performed animal experiments and
analyses including DSS and AOM/DSS procedures, Acquisition of data, Analysis and interpretation
of data; SKR, Assisted with animal procedures and analyses, Acquisition of data, Analysis and inter-
pretation of data; C-SC, SN, H-WP, Assisted with cell culture experiments and biochemical analyses,
Acquisition of data, Analysis and interpretation of data; IJ, Assisted with histological procedures and
analyses, Acquisition of data, Analysis and interpretation of data; IAS, Assisted with cell culture
experiments and biochemical analyses, Acquisition of data, Analysis and interpretation of data,
Drafting or revising the article; AH, Assisted with histological procedures and analyses, Acquisition
of data, Analysis and interpretation of data, Drafting or revising the article; YMS, JHL, Conception
and design, Analysis and interpretation of data, Drafting or revising the article
Author ORCIDs
Jun Hee Lee, http://orcid.org/0000-0002-2200-6011
Ethics
Animal experimentation: All animal studies were ethically approved (protocol approval numbers:
PRO00005712 and PRO00004019) and overseen by the University Committee on Use and Care of
Animals (UCUCA) at the University of Michigan.
Additional files
Major datasets
The following previously published datasets were used:
Database, license,
and accessibility
Ro et al. eLife 2016;5:e12204. DOI: 10.7554/eLife.12204 16 of 20
Research article Cell biology Human biology and medicine
Author(s) Year Dataset title Dataset URL information
2007 Oncomine 3.0: genes, pathways,
and networks in a collection of
18,000 cancer gene expression
profiles
https://www.oncomine.
com
PMID: 17356713
2008 Data from: Cross-species
comparison of human and mouse
intestinal polyps reveals conserved
mechanisms in adenomatous
polyposis coli (APC)-driven
tumorigenesis
https://www.oncomine.
com
PMID: 18403596
2006 Data from: Deciphering cellular
states of innate tumor drug
responses
https://www.oncomine.
com
PMID: 16542501
2010 Data from: A ’metastasis-prone’
signature for early-stage
mismatch-repair proficient
sporadic colorectal cancer patients
and its implications for possible
therapeutics
https://www.oncomine.
com
PMID: 20143136
2007 Data from: Transcriptional
recapitulation and subversion of
embryonic colon development by
mouse colon tumor models and
human colon cancer
https://www.oncomine.
com
PMID: 17615082
2012 Data from: Comprehensive
molecular characterization of
human colon and rectal cancer
https://www.oncomine.
com
PMID: 22810696
2010 Data from: Modeling oncogenic
signaling in colon tumors by
multidirectional analyses of
microarray data directed for
maximization of analytical
reliability
https://www.oncomine.
com
PMID: 20957034
2012 Data from: Comprehensive
molecular characterization of
human colon and rectal cancer
http://www.ncbi.nlm.nih.
gov/pmc/articles/
PMC3401966/bin/
NIHMS379461-supple-
ment-13.xlsx
PMID: 22810696
References
Agarwal S, Bell CM, Taylor SM, Moran RG. 2016. p53 Deletion or Hotspot Mutations Enhance mTORC1 Activity
by Altering Lysosomal Dynamics of TSC2 and Rheb. Molecular Cancer Research 14:66–77. doi: 10.1158/1541-
7786.MCR-15-0159, PMID: 26385560
Anderson ER, Taylor M, Xue X, Ramakrishnan SK, Martin A, Xie L, Bredell BX, Gardenghi S, Rivella S, Shah YM.
2013. Intestinal HIF2 promotes tissue-iron accumulation in disorders of iron overload with anemia. Proceedings
of the National Academy of Sciences of the United States of America 110:E4922–E4930. doi: 10.1073/pnas.
1314197110, PMID: 24282296
Bae SH, Sung SH, Oh SY, Lim JM, Lee SK, Park YN, Lee HE, Kang D, Rhee SG. 2013. Sestrins Activate Nrf2 by
Promoting p62-Dependent Autophagic Degradation of Keap1 and Prevent Oxidative Liver Damage. Cell
Metabolism 17:73–84. doi: 10.1016/j.cmet.2012.12.002, PMID: 23274085
Bertolotti A, Wang X, Novoa I, Jungreis R, Schlessinger K, Cho JH, West AB, Ron D. 2001. Increased sensitivity
to dextran sodium sulfate colitis in IRE1b-deficient mice. Journal of Clinical Investigation 107:585–593. doi: 10.
1172/JCI11476, PMID: 11238559
Bru¨ning A, Rahmeh M, Friese K. 2013. Nelfinavir and bortezomib inhibit mTOR activity via ATF4-mediated
sestrin-2 regulation. Molecular Oncology 7:1012–1018. doi: 10.1016/j.molonc.2013.07.010, PMID: 23916134
Budanov AV, Karin M. 2008. p53 Target Genes Sestrin1 and Sestrin2 Connect Genotoxic Stress and mTOR
Signaling. Cell 134:451–460. doi: 10.1016/j.cell.2008.06.028, PMID: 18692468
Budanov AV, Sablina AA, Feinstein E, Koonin EV, Chumakov PM. 2004. Regeneration of Peroxiredoxins by p53-
Regulated Sestrins, Homologs of Bacterial AhpD. Science 304:596–600. doi: 10.1126/science.1095569,
PMID: 15105503
Budanov AV, Shoshani T, Faerman A, Zelin E, Kamer I, Kalinski H, Gorodin S, Fishman A, Chajut A, Einat P,
Skaliter R, Gudkov AV, Chumakov PM, Feinstein E. 2002. Identification of a novel stress-responsive gene Hi95
involved in regulation of cell viability. Oncogene 21:6017–6031. doi: 10.1038/sj.onc.1205877, PMID: 12203114
Ro et al. eLife 2016;5:e12204. DOI: 10.7554/eLife.12204 17 of 20
Research article Cell biology Human biology and medicine
Cancer Genome Atlas Network. 2012. Comprehensive molecular characterization of human colon and rectal
cancer. Nature 487:330–337. doi: 10.1038/nature11252, PMID: 22810696
Cao SS, Zimmermann EM, Chuang B–M, Song B, Nwokoye A, Wilkinson JE, Eaton KA, Kaufman RJ. 2013. The
Unfolded Protein Response and Chemical Chaperones Reduce Protein Misfolding and Colitis in Mice.
Gastroenterology 144:989–1000. doi: 10.1053/j.gastro.2013.01.023
Chantranupong L, Wolfson RL, Orozco JM, Saxton RA, Scaria SM, Bar-Peled L, Spooner E, Isasa M, Gygi SP,
Sabatini DM. 2014. The Sestrins Interact with GATOR2 to Negatively Regulate the Amino-Acid-Sensing
Pathway Upstream of mTORC1. Cell Reports 9:1–8. doi: 10.1016/j.celrep.2014.09.014, PMID: 25263562
Ding B, Parmigiani A, Yang C, Budanov AV. 2015. Sestrin2 facilitates death receptor-induced apoptosis in lung
adenocarcinoma cells through regulation of XIAP degradation. Cell Cycle 14:3231–3241. doi: 10.1080/
15384101.2015.1084447, PMID: 26313705
Faller WJ, Jackson TJ, Knight JRP, Ridgway RA, Jamieson T, Karim SA, Jones C, Radulescu S, Huels DJ, Myant
KB, Dudek KM, Casey HA, Scopelliti A, Cordero JB, Vidal M, Pende M, Ryazanov AG, Sonenberg N, Meyuhas
O, Hall MN, et al. 2015. mTORC1-mediated translational elongation limits intestinal tumour initiation and
growth. Nature 517:497–500. doi: 10.1038/nature13896, PMID: 25383520
Fearon ER. 2011. Molecular Genetics of Colorectal Cancer. Annual Review of Pathology: Mechanisms of Disease
6:479–507. doi: 10.1146/annurev-pathol-011110-130235, PMID: 21090969
Feng Y, Sentani K, Wiese A, Sands E, Green M, Bommer GT, Cho KR, Fearon ER. 2013. Sox9 Induction, Ectopic
Paneth Cells, and Mitotic Spindle Axis Defects in Mouse Colon Adenomatous Epithelium Arising From
Conditional Biallelic Apc Inactivation. The American Journal of Pathology 183:493–503. doi: 10.1016/j.ajpath.
2013.04.013, PMID: 23769888
Feng Z, Hu W, de Stanchina E, Teresky AK, Jin S, Lowe S, Levine AJ. 2007. The Regulation of AMPK 1, TSC2,
and PTEN Expression by p53: Stress, Cell and Tissue Specificity, and the Role of These Gene Products in
Modulating the IGF-1-AKT-mTOR Pathways. Cancer Research 67:3043–3053. doi: 10.1158/0008-5472.CAN-06-
4149, PMID: 17409411
Feng Z, Levine AJ. 2010. The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53
protein. Trends in Cell Biology 20:427–434. doi: 10.1016/j.tcb.2010.03.004, PMID: 20399660
Fritz T, Niederreiter L, Adolph T, Blumberg RS, Kaser A. 2011. Crohn’s disease: NOD2, autophagy and ER stress
converge. Gut 60:1580–1588. doi: 10.1136/gut.2009.206466, PMID: 21252204
Gaspar C, Cardoso J, Franken P, Molenaar L, Morreau H, Mo¨slein G, Sampson J, Boer JM, de Menezes RX,
Fodde R. 2008. Cross-Species Comparison of Human and Mouse Intestinal Polyps Reveals Conserved
Mechanisms in Adenomatous Polyposis Coli (APC)-Driven Tumorigenesis. The American Journal of Pathology
172:1363–1380. doi: 10.2353/ajpath.2008.070851, PMID: 18403596
Graudens E, Boulanger V, Mollard C, Mariage-Samson R, Barlet X, Gre´my G, Couillault C, Laje´mi M, Piatier-
Tonneau D, Zaborski P, Eveno E, Auffray C, Imbeaud S. 2006. Deciphering cellular states of innate tumor drug
responses. Genome Biology 7:R19. doi: 10.1186/gb-2006-7-3-r19, PMID: 16542501
Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D, Taniguchi K, Yu G-Y, O¨sterreicher CH,
Hung KE, Datz C, Feng Y, Fearon ER, Oukka M, Tessarollo L, Coppola V, Yarovinsky F, Cheroutre H, Eckmann
L, Trinchieri G, et al. 2012. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated
tumour growth. Nature 491:254–258. doi: 10.1038/nature11465, PMID: 23034650
Hardiman KM, Liu J, Feng Y, Greenson JK, Fearon ER. 2014. Rapamycin Inhibition of Polyposis and Progression
to Dysplasia in a Mouse Model. PLoS ONE 9:e96023. doi: 10.1371/journal.pone.0096023, PMID: 24763434
Hay N, Sonenberg N. 2004. Upstream and downstream of mTOR. Genes & Development 18:1926–1945. doi: 10.
1101/gad.1212704, PMID: 15314020
Hong Y, Downey T, Eu KW, Koh PK, Cheah PY. 2010. A ‘metastasis-prone’ signature for early-stage mismatch-
repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics. Clinical &
Experimental Metastasis 27:83–90. doi: 10.1007/s10585-010-9305-4, PMID: 20143136
Kaiser S, Park Y-K, Franklin JL, Halberg RB, Yu M, Jessen WJ, Freudenberg J, Chen X, Haigis K, Jegga AG, Kong
S, Sakthivel B, Xu H, Reichling T, Azhar M, Boivin GP, Roberts RB, Bissahoyo AC, Gonzales F, Bloom GC, et al.
2007. Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor
models and human colon cancer. Genome Biology 8:R131. doi: 10.1186/gb-2007-8-7-r131, PMID: 17615082
Kaser A, Lee A-H, Franke A, Glickman JN, Zeissig S, Tilg H, Nieuwenhuis EES, Higgins DE, Schreiber S, Glimcher
LH, Blumberg RS. 2008. XBP1 Links ER Stress to Intestinal Inflammation and Confers Genetic Risk for Human
Inflammatory Bowel Disease. Cell 134:743–756. doi: 10.1016/j.cell.2008.07.021, PMID: 18775308
Kim H, An S, Ro S-H, Teixeira F, Jin Park G, Kim C, Cho C-S, Kim J-S, Jakob U, Hee Lee J, Cho U-S. 2015a.
Janus-faced Sestrin2 controls ROS and mTOR signalling through two separate functional domains. Nature
Communications 6:10025. doi: 10.1038/ncomms10025
Kim JS, Ro S-H, Kim M, Park H-W, Semple IA, Park H, Cho U-S, Wang W, Guan K-L, Karin M, Lee JH. 2015b.
Sestrin2 inhibits mTORC1 through modulation of GATOR complexes. Scientific Reports 5:9502. doi: 10.1038/
srep09502
Lee JH, Budanov AV, Karin M. 2013. Sestrins Orchestrate Cellular Metabolism to Attenuate Aging. Cell
Metabolism 18:792–801. doi: 10.1016/j.cmet.2013.08.018, PMID: 24055102
Lee JH, Budanov AV, Park EJ, Birse R, Kim TE, Perkins GA, Ocorr K, Ellisman MH, Bodmer R, Bier E, Karin M.
2010. Sestrin as a Feedback Inhibitor of TOR That Prevents Age-Related Pathologies. Science 327:1223–1228.
doi: 10.1126/science.1182228, PMID: 20203043
Lee JH, Budanov AV, Talukdar S, Park EJ, Park HL, Park H-W, Bandyopadhyay G, Li N, Aghajan M, Jang I, Wolfe
AM, Perkins GA, Ellisman MH, Bier E, Scadeng M, Foretz M, Viollet B, Olefsky J, Karin M. 2012. Maintenance of
Ro et al. eLife 2016;5:e12204. DOI: 10.7554/eLife.12204 18 of 20
Research article Cell biology Human biology and medicine
Metabolic Homeostasis by Sestrin2 and Sestrin3. Cell Metabolism 16:311–321. doi: 10.1016/j.cmet.2012.08.
004, PMID: 22958918
Nambiar PR, Nakanishi M, Gupta R, Cheung E, Firouzi A, Ma XJ, Flynn C, Dong M, Guda K, Levine J, Raja R,
Achenie L, Rosenberg DW. 2004. Genetic signatures of High- and Low-Risk Aberrant Crypt Foci in a Mouse
Model of Sporadic Colon Cancer. Cancer Research 64:6394–6401. doi: 10.1158/0008-5472.CAN-04-0933,
PMID: 15374946
Nogueira V, Park Y, Chen C-C, Xu P-Z, Chen M-L, Tonic I, Unterman T, Hay N. 2008. Akt Determines Replicative
Senescence and Oxidative or Oncogenic Premature Senescence and Sensitizes Cells to Oxidative Apoptosis.
Cancer Cell 14:458–470. doi: 10.1016/j.ccr.2008.11.003, PMID: 19061837
Ozcan U, Ozcan L, Yilmaz E, Du¨vel K, Sahin M, Manning BD, Hotamisligil GS. 2008. Loss of the Tuberous
Sclerosis Complex Tumor Suppressors Triggers the Unfolded Protein Response to Regulate Insulin Signaling
and Apoptosis. Molecular Cell 29:541–551. doi: 10.1016/j.molcel.2007.12.023, PMID: 18342602
Park EJ, Lee JH, Yu G-Y, He G, Ali SR, Holzer RG, O¨sterreicher CH, Takahashi H, Karin M. 2010. Dietary and
Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF Expression. Cell
140:197–208. doi: 10.1016/j.cell.2009.12.052, PMID: 20141834
Park H-W, Park H, Ro S-H, Jang I, Semple IA, Kim DN, Kim M, Nam M, Zhang D, Yin L, Lee JH. 2014.
Hepatoprotective role of Sestrin2 against chronic ER stress. Nature Communications 5:4233. doi: 10.1038/
ncomms5233, PMID: 24947615
Parmigiani A, Nourbakhsh A, Ding B, Wang W, Kim YC, Akopiants K, Guan K-L, Karin M, Budanov AV. 2014.
Sestrins Inhibit mTORC1 Kinase Activation through the GATOR Complex. Cell Reports 9:1281–1291. doi: 10.
1016/j.celrep.2014.10.019, PMID: 25457612
Peng M, Yin N, Li MO. 2014. Sestrins Function as Guanine Nucleotide Dissociation Inhibitors for Rag GTPases to
Control mTORC1 Signaling. Cell 159:122–133. doi: 10.1016/j.cell.2014.08.038, PMID: 25259925
Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-
Beal C, Kulkarni P, Varambally S, Ghosh D, Chinnaiyan AM. 2007. Oncomine 3.0: Genes, Pathways, and
Networks in a Collection of 18,000 Cancer Gene Expression Profiles. Neoplasia 9:166–180. doi: 10.1593/neo.
07112, PMID: 17356713
Riley T, Sontag E, Chen P, Levine A. 2008. Transcriptional control of human p53-regulated genes. Nature
Reviews Molecular Cell Biology 9:402–412. doi: 10.1038/nrm2395, PMID: 18431400
Ro S-H, Nam M, Jang I, Park H-W, Park H, Semple IA, Kim M, Kim JS, Park H, Einat P, Damari G, Golikov M,
Feinstein E, Lee JH. 2014a. Sestrin2 inhibits uncoupling protein 1 expression through suppressing reactive
oxygen species. Proceedings of the National Academy of Sciences of the United States of America 111:7849–
7854. doi: 10.1073/pnas.1401787111
Ro S-H, Semple IA, Park H, Park H, Park H-W, Kim M, Kim JS, Lee JH. 2014b. Sestrin2 promotes Unc-51-like
kinase 1 mediated phosphorylation of p62/sequestosome-1. FEBS Journal 281:3816–3827. doi: 10.1111/febs.
12905
Rosenberg DW, Giardina C, Tanaka T. 2009. Mouse models for the study of colon carcinogenesis.
Carcinogenesis 30:183–196. doi: 10.1093/carcin/bgn267, PMID: 19037092
Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE, Chumakov PM. 2005. The antioxidant
function of the p53 tumor suppressor. Nature Medicine 11:1306–1313. doi: 10.1038/nm1320, PMID: 16286925
Sanli T, Linher-Melville K, Tsakiridis T, Singh G. 2012. Sestrin2 Modulates AMPK Subunit Expression and Its
Response to Ionizing Radiation in Breast Cancer Cells. PLoS ONE 7:e32035. doi: 10.1371/journal.pone.
0032035, PMID: 22363791
Siegel RL, Miller KD, Jemal A. 2015. Cancer statistics, 2015. CA: A Cancer Journal for Clinicians 65:5–29. doi: 10.
3322/caac.21254, PMID: 25559415
Skrzypczak M, Goryca K, Rubel T, Paziewska A, Mikula M, Jarosz D, Pachlewski J, Oledzki J, Ostrowski J,
Ostrowsk J. 2010. Correction: Modeling Oncogenic Signaling in Colon Tumors by Multidirectional Analyses of
Microarray Data Directed for Maximization of Analytical Reliability. PLoS ONE 5. doi: 10.1371/annotation/
8c585739-a354-4fc9-a7d0-d5ae26fa06ca, PMID: 20957034
Takahashi M, Wakabayashi K. 2004. Gene mutations and altered gene expression in azoxymethane-induced
colon carcinogenesis in rodents. Cancer Science 95:475–480. doi: 10.1111/j.1349-7006.2004.tb03235.x,
PMID: 15182426
Terzic´ J, Grivennikov S, Karin E, Karin M. 2010. Inflammation and Colon Cancer. Gastroenterology 138:2101–
2114. doi: 10.1053/j.gastro.2010.01.058
Thiem S, Pierce TP, Palmieri M, Putoczki TL, Buchert M, Preaudet A, Farid RO, Love C, Catimel B, Lei Z, Rozen S,
Gopalakrishnan V, Schaper F, Hallek M, Boussioutas A, Tan P, Jarnicki A, Ernst M. 2013. mTORC1 inhibition
restricts inflammation-associated gastrointestinal tumorigenesis in mice. Journal of Clinical Investigation 123:
767–781. doi: 10.1172/JCI65086, PMID: 23321674
Thorsteinsdottir S, Gudjonsson T, Nielsen OH, Vainer B, Seidelin JB. 2011. Pathogenesis and biomarkers of
carcinogenesis in ulcerative colitis. Nature Reviews Gastroenterology & Hepatology 8:395–404. doi: 10.1038/
nrgastro.2011.96, PMID: 21647200
Velasco-Miguel S, Buckbinder L, Jean P, Gelbert L, Talbott R, Laidlaw J, Seizinger B, Kley N. 1999. PA26, a novel
target of the p53 tumor suppressor and member of the GADD family of DNA damage and growth arrest
inducible genes. Oncogene 18:127–137. doi: 10.1038/sj.onc.1202274, PMID: 9926927
Wang M, Kaufman RJ. 2014. The impact of the endoplasmic reticulum protein-folding environment on cancer
development. Nature Reviews Cancer 14:581–597. doi: 10.1038/nrc3800, PMID: 25145482
Ro et al. eLife 2016;5:e12204. DOI: 10.7554/eLife.12204 19 of 20
Research article Cell biology Human biology and medicine
Wolfson RL, Chantranupong L, Saxton RA, Shen K, Scaria SM, Cantor JR, Sabatini DM. 2016. Sestrin2 is a leucine
sensor for the mTORC1 pathway. Science 351:43–48. doi: 10.1126/science.aab2674, PMID: 26449471
Woo HA, Bae SH, Park S, Rhee SG. 2009. Sestrin 2 Is Not a Reductase for Cysteine Sulfinic Acid of
Peroxiredoxins. Antioxidants & Redox Signaling 11:739–745. doi: 10.1089/ars.2008.2360, PMID: 19113821
Xue X, Ramakrishnan S, Anderson E, Taylor M, Zimmermann EM, Spence JR, Huang S, Greenson JK, Shah YM.
2013. Endothelial PAS Domain Protein 1 Activates the Inflammatory Response in the Intestinal Epithelium to
Promote Colitis in Mice. Gastroenterology 145:831–841. doi: 10.1053/j.gastro.2013.07.010, PMID: 23860500
Ye J, Palm W, Peng M, King B, Lindsten T, Li MO, Koumenis C, Thompson CB. 2015. GCN2 sustains mTORC1
suppression upon amino acid deprivation by inducing Sestrin2. Genes & Development 29:2331–2336. doi: 10.
1101/gad.269324.115, PMID: 26543160
Young RM, Ackerman D, Quinn ZL, Mancuso A, Gruber M, Liu L, Giannoukos DN, Bobrovnikova-Marjon E, Diehl
JA, Keith B, Simon MC. 2013. Dysregulated mTORC1 renders cells critically dependent on desaturated lipids
for survival under tumor-like stress. Genes & Development 27:1115–1131. doi: 10.1101/gad.198630.112,
PMID: 23699409
Zhu H, Li YR. 2012. Oxidative stress and redox signaling mechanisms of inflammatory bowel disease: updated
experimental and clinical evidence. Experimental Biology and Medicine 237:474–480. doi: 10.1258/ebm.2011.
011358, PMID: 22442342
Zoncu R, Efeyan A, Sabatini DM. 2011. mTOR: from growth signal integration to cancer, diabetes and ageing.
Nature Reviews Molecular Cell Biology 12:21–35. doi: 10.1038/nrm3025, PMID: 21157483
Ro et al. eLife 2016;5:e12204. DOI: 10.7554/eLife.12204 20 of 20
Research article Cell biology Human biology and medicine
